The present application claims priority from Japanese patent application JP 2007-322043 filed on Dec. 13, 2007 and JP 2008-274783 filed on Oct. 24, 2008, the content of which is hereby incorporated by reference into this application.
1. Field of the Invention
The present invention relates to a nucleic acid (DNA or RNA) detection method. More specifically, the present invention relates to a gene detection method comprising the step of specifically hybridizing an oligonucleotide probe to a sample (single-stranded or double-stranded nucleic acid such as genomic DNA or RNA or PCR products).
2. Background Art
The analysis of gene expression levels with high sensitivity and wide dynamic range plays an exceedingly important role in functional analysis of genes or in disease study or diagnosis. For example, the test of infection such as hepatitis, HIV, tuberculosis germs, or sexually transmitted infection requires conducing gene quantification on an infectious pathogen at the initial stage for circumventing infection spread or effectively treating the infection. Alternatively, pharmaceutical fields require conducting quantification on a gene that differs in a disease-specific manner, for identifying a target in drug discovery or evaluating the effects of a drug.
Such gene quantification generally involves detecting the gene of interest after amplification by a method such as PCR (Polymerase Chain Reaction), NASBA (Nucleic Acid Sequence Based Amplification), or LAMP (Loop mediated isothermal amplification). A probe used in the detection is, for example, a TaqMan, Molecular Beacon, or Quenching probe. Of them, the detection using the TaqMan probe requires using an enzyme having 5′→3′ exonuclease activity. Therefore, this TaqMan probe is applicable to a PCR amplification method using DNA polymerase having 5′→3′ exonuclease activity and however, cannot be used in NASBA or LAMP, which is an isothermal amplification method that requires using DNA or RNA polymerase having strand displacement activity but free from 5′→3′ exonuclease activity. Thus, detection probes that can be used in LAMP or NASBA are Molecular Beacon and Quenching probes.
The Molecular Beacon probe is designed such that a sequence therein hybridizes to a target nucleic acid. In addition, this probe needs to be designed such that the stem sequence takes a stable hairpin structure in the absence of the target nucleic acid. This is because if the stem sequence fails to take the stable hairpin structure, incomplete quenching occurs, leading to increase in background. The prevention thereof requires designing, with care, the sequence that hybridizes to the target nucleic acid and the stem sequence. As a result, the probe sequence is disadvantageously designed with a limited degree of flexibility.
On the other hand, the Quenching probe is labeled at the 5′ or 3′ end with a fluorophore. This probe employs the phenomenon in which fluorescence is quenched through the interaction between the fluorophore in the probe bound with a target nucleic acid and guanine in the target nucleic acid sequence. Fluorescence is quenched in the presence of the target nucleic acid and is not quenched in the absence of the target nucleic acid. Therefore, the presence or absence of the target nucleic acid can be determined. However, the fluorophore that is quenched through its interaction with guanine is limited to Pacific Blue, TAMRA, CR6G, BODIPY FL, or the like and is not suitable for multicolor detection. Moreover, the probe must be designed such that the probe is located at a position that permits the interaction with guanine in the target nucleic acid sequence. Thus, the probe is also disadvantageously designed with a limited degree of flexibility.
A main object of the present invention is to provide a probe that is designed with a high degree of flexibility to be applicable to detection by a nucleic acid amplification method using DNA polymerase free from 5′→3′ exonuclease activity.
To attain the object, the present inventors have found a method wherein the presence or absence of a target nucleic acid is determined by hybridizing first and second probes labeled with a fluorophore and a quencher, respectively (and vice versa) to the target nucleic acid in tandem such that a fluorescent signal from the fluorophore is quenched.
The probes used in the present invention are a first probe which hybridizes to the target nucleic acid and a second probe which hybridizes thereto on the 3′ end side of the first probe to give a gap of 0 to 10 bases, preferably 0 to 3 bases, most preferably 1 base, between the first and second probes. The first probe is labeled at the 3′ end with a quencher. The second probe is labeled at the 5′ end with a fluorophore and labeled with a phosphate group or an amino group at the 3′ end to prevent the second probe from being extended.
When the target nucleic acid is absent in a reaction solution, the first and second probes are present each independently in the reaction solution from which fluorescence derived from the second probe is detected. On the other hand, when the target nucleic acid is present, the first and second probes hybridize to the target nucleic acid. In this case, the first and second probes hybridize thereto in tandem to give the gap. Therefore, the quencher as a label at the 3′ end of the first probe and the fluorophore as a label at the 5′ end of the second probe are located close to each other such that a fluorescent signal from the fluorophore is quenched through fluorescent resonance energy transfer.
In the course of nucleic acid amplification reaction, the target nucleic acids are formed as the reaction progresses. Therefore, the first and second probes gradually hybridize to the amplified target nucleic acids. Specifically, fluorescent signal intensity from the reaction solution is decreased as time passes. In case of a conventional Molecular Beacon or TaqMan probe, fluorescent signal intensity increases as the target nucleic acid is amplified. The timing when the fluorescent signal intensity exceeds a certain threshold value depends on the amount of the target nucleic acid before the initiation of reaction. On the other hand, in case of the nucleic acid detection probe of the present invention, fluorescent signal intensity decreases as the target nucleic acid is amplified. The timing when the fluorescent signal intensity falls below a certain threshold value depends on the amount of the target nucleic acid before the initiation of reaction. Thus, a calibration curve is prepared in the same way as in the conventional Molecular Beacon or TaqMan probe by plotting the amount of a fluorescent signal decreased, calculated from the absolute value of the fluorescent signal. Based on the calibration curve, the target nucleic acid can be quantified.
Alternatively, the first probe may be labeled at the 3′ end with a fluorophore, and the second probe may be labeled at the 5′ end with a quencher. In this case as well, the first and second probes hybridize to the target nucleic acid to give a gap of 0 to 10 bases, preferably 0 to 3 bases, most preferably 1 base, between the first and second probes such that a fluorescent signal from the fluorophore is quenched through the interaction between the fluorophore and the quencher. In this case as well, the second probe is labeled at the 3′ end to prevent the second probe from being extended.
Alternatively, the first and second probes may be ligated as one probe. Specifically, a sequence portion corresponding to the first probe and a sequence portion corresponding to the second probe are designed to hybridize to the target nucleic acid in tandem. These sequence portions are ligated via a sequence portion which does not hybridize to the target nucleic acid to prepare a probe labeled at the 5′ end with a fluorophore and labeled at the 3′ end with a quencher. This sequence portion which does not hybridize thereto has a length that is equal to or larger than the total length of the sequence portion corresponding to the first probe and the sequence portion corresponding to the second probe and needs to be a length on the order of a few hundred bases. Preferably, the sequence portion is 50 to 200 bases in length. When the target nucleic acid is absent, the probe takes a linear form. Therefore, the fluorophore and the quencher as labels at the 5′ and 3′ ends, respectively, of the probe are kept apart in the reaction solution from which fluorescence is detected. When the target nucleic acid is present, the 5′ and 3′ ends of the probe hybridize to the target nucleic acid in tandem. As a result, the fluorophore and the quencher are located close to each other such that a fluorescent signal from the fluorophore is quenched through fluorescent resonance energy transfer. Thus, the state in which the target nucleic acid are amplified as the reaction progresses can be measured using even the first and second probes that are ligated, in the same way as in the use of the first and second probes described above. Alternatively, the probe may be labeled at the 3′ end with a fluorophore and at the 5′ end with a quencher.
Thus, according to the present invention, a probe can be designed without sequence limitations on a target sequence.
Moreover, the present invention provides a nucleic acid detection probe kit shown below.
In one embodiment, a kit comprises two oligonucleotide probes having sequences which respectively recognize a target nucleic acid and hybridize to the target nucleic acid in tandem to give a gap of 0 to 10 bases, preferably 0 to 3 bases, most preferably 1 base, between the probes. One of the oligonucleotide probes flanking this gap is labeled with a fluorophore, and the other oligonucleotide probe is labeled with a quencher.
In an alternative embodiment, the first and second probes are ligated as one oligonucleotide probe labeled at the 5′ and 3′ ends with a fluorophore and a quencher, respectively. This oligonucleotide probe hybridizes to the target nucleic acid in tandem such that the fluorophore and the quencher are located in proximity to each other.
In an alternative embodiment, an oligonucleotide probe may be modified at the end with a functional group such as an amino group or with biotin such that a user may label the oligonucleotide probe with the fluorophore or quencher. In this case, a kit can additionally comprise a fluorophore or quencher having a portion introduced for reaction with the functional group.
The kit of the present invention comprises the oligonucleotide probe(s) as an essential component and may also comprise other reagents necessary for detection reaction, for example, a reaction buffer, substrate nucleotides, amplification primers, and enzymes.
In the present invention, two or one oligonucleotide probe(s) labeled with a fluorophore and a quencher are allowed to act on a target gene, and changes in fluorescent signal generated through fluorescent resonance energy transfer are detected. As a result, a nucleic acid detection probe that is functionally similar to a conventional Molecular Beacon or Quenching probe hardly designed with a high degree of flexibility can be designed regardless of a target gene sequence.
Hereinafter, the present invention will be described specifically with reference to the drawings.
A first flow of the present invention is shown in
In this context, examples of the fluorophore that can be used in the present invention can include FAM, TET, HEX, Fluorescein, FITC, CR6G, ROX, TAMRA, JOE, Texas Red, Oregon Green, Yakima Yellow, Pacific Blue, Cascade Blue, Cy Dye series, CAL Fluor series, ALEXA series, Rhodamine series, and BODIPY series. Examples of the quencher that can be used in the present invention can include TAMRA, Dabcyl, Eclipse® Dark Quencher, BHQ series, and DDQ series. Examples of possible combinations of the fluorophore and the quencher used in the present invention include, but not limited to, combinations of ALEXA 350 with BHQ-0, FAM with BHQ-1, ROX with BHQ-2, Cy5 with BHQ-3, TET with Dabcyl, Fluorescein with TAMRA, HEX with DDQ I, Rhodamine 6G with DDQ II, and Yakima Yellow with Eclipse® Dark Quencher.
A second flow of the present invention is shown in
A third flow of the present invention is shown in
Using the first and second probes of the present invention, the presence or absence of the target nucleic acid can be determined by measuring the fluorescent intensities of the solution before and after PCR amplification reaction. In this case, the Tm values of the first and second probes are set to temperatures about 5 to 10° C. higher than those of primers. This is because fluorescence measurement is conducted during annealing, and thus, the probes must hybridize with reliability to the target nucleic acid before the primers do. For example, the Tm values of primers used in [Example 2] described later are 59.0° C. (forward primer) and 57.2° C. (reverse primer). By contrast, the Tm values of the probes are 65.3° C. (first probe) and 66.3° C. (second probe).
A graph 20 of
In general, the ratio between fluorescent intensity in the absence of a target nucleic acid and fluorescent intensity in the presence of a target nucleic acid serves as an index for showing the sensitivity of a detection probe. In the present invention, fluorescent intensity is large in the absence of the target nucleic acid, and decrease in fluorescent signal through fluorescent energy transfer is observed in the presence of the target nucleic acid. Thus, the fluorescent intensity ratio between before decrease of fluorescent intensity immediately after the initiation of reaction and after decrease of fluorescent intensity is defined as a quenching rate that serves as an index for showing a decrement in fluorescent signal. A probe with a high quenching rate can be determined as a probe excellent in detection sensitivity.
In the present invention, the first and second probes need to simultaneously hybridize to the target nucleic acid. This is because even if only the first probe, or only the second probe, hybridizes to the target nucleic acid, quenching effects are not observed, resulting in unsuccessful determination of the presence or absence of the target nucleic acid. The simultaneous hybridization of the first and second probes to the target nucleic acid requires adjusting the Tm values of the first and second probes to as equal values as possible.
Alternatively, the presence or absence of the target nucleic acid can also be determined in real time by measuring fluorescent intensity during amplification reaction. From the real-time measurement results, the target nucleic acid can also be quantified.
Hereinafter, the present invention will be described with reference to Examples. However, the present invention is not intended to be limited to these Examples.
Tris-HCl pH 8.2 (10 mM), KCl (20 mM), (NH4)2SO4 (5 mM), MgSO4 (2 mM), dATP (0.25 mM), dCTP (0.25 mM), dGTP (0.25 mM), dTTP (0.25 mM), Triton X-100 (0.05%), Betaine (250 mM)
Bst DNA polymerase 8 U
To confirm whether a target nucleic acid can be detected using nucleic acid detection probes of the present invention described in
The first detection probe is labeled at the 3′ end with a quencher BHQ-1 and has a sequence hybridizing to the cytochrome P450 gene as a target nucleic acid. Moreover, the second detection probe is labeled at the 5′ end with a fluorophore FAM and phosphorylated at the 3′ end to prevent the probe from being extended. The second detection probe also has a sequence hybridizing to the cytochrome P450 gene and is designed to hybridize thereto to give a gap of 1 base downstream of the first detection probe.
The human genomic DNA as a template was added to the reaction solution containing the primers, the oligonucleotide probes, and the Bst DNA polymerase described in the paragraph 1., and the solution was incubated for 90 minutes in a heat block set to 60° C. Then, the fluorescent signal of the reaction solution was measured using the fluorescence plate reader.
The measurement results are shown in
Tricine-KOH pH 8.0 (40 mM), KCl (16 mM), MgSO4 (3.5 mM), dATP (0.4 mM), dCTP (0.4 mM), dGTP (0.4 mM), dTTP (0.4 mM), BSA (3.75 mg/mL)
TITANIUM Taq polymerase 2 U (Clontech)
To confirm whether a target nucleic acid can be detected using nucleic acid detection probes of the present invention described in
In this context, the TITANIUM Taq polymerase (Clontech) is an N-terminal deletion mutant of Taq polymerase, which is deficient in 5′→3′ exonuclease activity due to this deletion. Therefore, the first and second detection probes contained in the reaction solution hybridize without degradation to the amplification product. As a result, fluorescence is quenched through the fluorescent resonance energy transfer between the probes. The first detection probe is labeled at the 3′ end with a fluorophore FAM and has a sequence hybridizing to the cytochrome P450 gene as a target nucleic acid. Moreover, the second detection probe is labeled at the 5′ end with a quencher BHQ-1 and aminated at the 3′ end to prevent the probe from being extended. This probe also has a sequence hybridizing to the cytochrome P450 gene and is designed to hybridize thereto to give a gap of 1 base downstream of the first detection probe.
The human genomic DNA as a template was added to the reaction solution containing the primers, the oligonucleotide probes, and the TITANIUM Taq polymerase described in the paragraph 1. Changes in the fluorescent signal intensity of the reaction solution were measured over time using the real-time PCR detector set to perform 60 thermal cycles each involving steps at 95° C. for 20 seconds and at 55° C. for 40 seconds.
The measurement results are shown in a graph 40 in
The underlined parts hybridize to a template.
In Example 3, Gene Taq Universal Buffer (Nippon Gene Co., Ltd.) was used as a reaction solution. The reaction solution prepared contained dATP (0.2 mM), dCTP (0.2 mM), dGTP (0.2 mM), and dTTP (0.2 mM).
Recombinant Taq DNA Polymerase: Gene Taq 0.625 U (Nippon Gene Co., Ltd.)
To confirm whether a target nucleic acid can be detected using a nucleic acid detection probe of the present invention described in
In this context, the Gene Taq (Nippon Gene Co., Ltd.) is deficient in endogenous 5′→3′ exonuclease activity due to the N-terminal partial deletion of wild-type Taq DNA polymerase. Therefore, the detection probe contained in the reaction solution hybridizes without degradation to the amplification product. As a result, fluorescence is quenched through the fluorescent resonance energy transfer between the labeled ends of the probe. The detection probe is labeled at the 3′ end with a quencher BHQ-1 and at the 5′ end with a fluorophore FAM. The detection probe is designed such that the 18-base sequence (gat gag ccg atc gtc aga: SEQ ID NO: 15) from the 3′ end and the 19-base sequence (tgt tgg gtc gcg aaa ggc c: SEQ ID NO: 16) from the 5′ end hybridize to the HCV gene in tandem to give a gap of 1 base.
The cDNA as a template was added to the reaction solution containing the primers, the oligonucleotide probe, and the Gene Taq described in the paragraph 1., and subjected to 40 thermal cycles each involving steps at 95° C. for 20 seconds and at 55° C. for 40 seconds. Then, the fluorescent signal of the reaction solution was measured using the fluorescence plate reader.
The measurement results are shown in a graph 45 in
In Example 4, Gene Taq Universal Buffer (Nippon Gene Co., Ltd.) was used as a reaction solution. The reaction solution prepared contained dATP (0.2 mM), dCTP (0.2 mM), dGTP (0.2 mM), and dTTP (0.2 mM).
Recombinant Taq DNA Polymerase: Gene Taq 0.625 U (Nippon Gene Co., Ltd.)
To confirm whether a target nucleic acid can be detected using nucleic acid detection probes of the present invention described in
In this context, the Gene Taq (Nippon Gene Co., Ltd.) is deficient in endogenous 5′→3′ exonuclease activity due to the N-terminal partial deletion of wild-type Taq DNA polymerase. Therefore, the detection probes contained in the reaction solution hybridize without degradation to the amplification product. As a result, fluorescence is quenched through the fluorescent resonance energy transfer between the probes.
The first detection probe represented by SEQ ID NO: 19 is labeled at the 3′ end with a quencher BHQ-0 and has a sequence hybridizing to the bacteriophage phi X174 genome as a target nucleic acid. Moreover, the second detection probe represented by SEQ ID NO: 21 is labeled at the 5′ end with a fluorophore ALEXA 350 and aminated at the 3′ end to prevent the probe from being extended. The second detection probe represented by SEQ ID NO: 21 also has a sequence hybridizing to the bacteriophage phi X174 genome and is designed to hybridize thereto to give a gap of 1 base downstream of the first detection probe represented by SEQ ID NO: 19.
Moreover, the first detection probe represented by SEQ ID NO: 20 has the same nucleotide sequence as that of the first detection probe represented by SEQ ID NO: 19 and is labeled at the 3′ end with a quencher DABCYL. The second detection probe represented by SEQ ID NO: 22 has the same nucleotide sequence as that of the second detection probe represented by SEQ ID NO: 21. The second detection probe represented by SEQ ID NO: 22 is labeled at the 5′ end with a fluorophore ALEXA 790 and aminated at the 3′ end to prevent the probe from being extended. When the first detection probe represented by SEQ ID NO: 20 and the second detection probe represented by SEQ ID NO: 22 are used in combination, the second detection probe hybridizes to the bacteriophage phi X174 genome to give a gap of 1 base downstream of the first detection probe, in the same way as in the use of the first detection probe represented by SEQ ID NO: 19 and the second detection probe represented by SEQ ID NO: 21 in combination.
The genomic DNA as a template was added to the reaction solution containing the primers, the first and second detection probes (combination of SEQ ID NOs: 19 and 21 or combination of SEQ ID NOs: 20 and 22), and the Gene Taq described in the paragraph 1., and subjected to 45 thermal cycles each involving steps at 95° C. for 15 seconds and at 60° C. for 60 seconds. Then, the fluorescent signal of the reaction solution was measured using the fluorophotometer.
The measurement results are shown in a graph 50 in
Tricine-KOH pH 8.0 (40 mM), KCl (16 mM), MgSO4 (3.5 mM), dATP (0.4 mM), dCTP (0.4 mM), dGTP (0.4 mM), dTTP (0.4 mM), BSA (3.75 mg/mL)
TITANIUM Taq polymerase 2 U (Clontech)
To confirm whether a target nucleic acid can be genotyped using nucleic acid detection probes of the present invention described in
In this context, the TITANIUM Taq polymerase (Clontech) is an N-terminal deletion mutant of Taq polymerase, which is deficient in 5′→3′ exonuclease activity due to this deletion. Therefore, the first and second detection probes contained in the reaction solution hybridize without degradation to the amplification product. As a result, fluorescence is quenched through the fluorescent resonance energy transfer between the probes.
The first detection probes represented by SEQ ID NOs: 25, 26, 27, and 28 are labeled at the 3′ end with a quencher DABCYL and have sequences hybridizing to the gag region as a target nucleic acid in subtypes A, B, C, and CRF (Circulating Recombinant form) AE, respectively, of the HIV-1 virus genome. Moreover, the second detection probes represented by SEQ ID NOs: 29, 30, 31, and 32 are labeled at the 5′ end with fluorophores ALEXA 350, ALEXA 430, ALEXA 594, and ALEXA 790, respectively and aminated at the 3′ end to prevent the probe from being extended. These second probes also have sequences hybridizing to the gag region as a target nucleic acid in subtypes A, B, C, and CRF (Circulating Recombinant form) AE, respectively, of the HIV-1 virus genome and are designed to hybridize thereto downstream of the first detection probe hybridizing to the same subtype. Specifically, to the subtype A, the second detection probe of SEQ ID NO: 29 hybridizes downstream of the first detection probe of SEQ ID NO: 25; to the subtype B, the second detection probe of SEQ ID NO: 30 hybridizes downstream of the first detection probe of SEQ ID NO: 26; to the subtype C, the second detection probe of SEQ ID NO: 31 hybridizes downstream of the first detection probe of SEQ ID NO: 27; and to the subtype CRF AE, the second detection probe of SEQ ID NO: 32 hybridizes downstream of the first detection probe of SEQ ID NO: 28.
The HIV-1 virus genome as a template was added to the reaction solution containing the primers, the first and second detection probes (combination of SEQ ID NOs: 25 and 29, combination of SEQ ID NOs: 26 and 30, combination of SEQ ID NOs: 27 and 31, or combination of SEQ ID NOs: 28 and 32), and the TITANIUM Taq polymerase described in the paragraph 1., and subjected to PCR under conditions of 40 thermal cycles each involving steps at 95° C. for 20 seconds and at 55° C. for 40 seconds. Fluorescent intensities at 55° C. respectively obtained by excitation with a white light source were measured every cycle through a band-pass filter which exhibited a passband of 30-nm bandwidth at a center wavelength of 440 nm (for ALEXA 350), 30-nm bandwidth at a center wavelength of 540 nm (for ALEXA 430), 30-nm bandwidth at a center wavelength of 620 nm (for ALEXA 594), or 30-nm bandwidth at a center wavelength of 810 nm (for ALEXA 790).
The measurement results are shown in
According to the present invention, the presence or absence of a target nucleic acid can be determined based on changes in the fluorescent intensity of a reaction solution attributed to the hybridization of two oligonucleotide probes thereto. Moreover, the oligonucleotide probes according to the present invention are designed with a high degree of flexibility and are applicable to various fluorophores. Therefore, the oligonucleotide probes according to the present invention facilitate real-time multiplex detection during the amplification reaction of trace amounts of nucleic acids, wherein plural kinds of target nucleic acids are simultaneously detected using plural fluorophores. Thus, the present invention is useful in, for example, medical or life science fields such as gene diagnosis, which require amplifying trace amounts of nucleic acids.
SEQ ID NO: 1—Description of Artificial Sequence: forward inner amplification primer used in the present invention
SEQ ID NO: 2—Description of Artificial Sequence: forward outer amplification primer used in the present invention
SEQ ID NO: 3—Description of Artificial Sequence: reverse inner amplification primer used in the present invention
SEQ ID NO: 4—Description of Artificial Sequence: reverse outer amplification primer used in the present invention
SEQ ID NO: 5—Description of Artificial Sequence: first detection oligonucleotide probe used in the present invention
SEQ ID NO: 6—Description of Artificial Sequence: second detection oligonucleotide probe used in the present invention
SEQ ID NO: 7—Description of Artificial Sequence: forward primer used in the present invention
SEQ ID NO: 8—Description of Artificial Sequence: reverse primer used in the present invention
SEQ ID NO: 9—Description of Artificial Sequence: first detection oligonucleotide probe used in the present invention
SEQ ID NO: 10—Description of Artificial Sequence: second detection oligonucleotide probe used in the present invention
SEQ ID NO: 11—Description of Artificial Sequence: forward primer used in the present invention
SEQ ID NO: 12—Description of Artificial Sequence: reverse primer used in the present invention
SEQ ID NO: 13—Description of Artificial Sequence: reverse transcription primer used in the present invention
SEQ ID NO: 14—Description of Artificial Sequence: detection oligonucleotide probe used in the present invention
SEQ ID NO: 15—sequence at 3′ end hybridizing to HCV gene
SEQ ID NO: 16—sequence at 5′ end hybridizing to HCV gene
SEQ ID NO: 17—Description of Artificial Sequence: forward primer used in the present invention
SEQ ID NO: 18—Description of Artificial Sequence: reverse primer used in the present invention
SEQ ID NO: 19—Description of Artificial Sequence: first detection oligonucleotide probe used in the present invention
SEQ ID NO: 20—Description of Artificial Sequence: first detection oligonucleotide probe used in the present invention
SEQ ID NO: 21—Description of Artificial Sequence: second detection oligonucleotide probe used in the present invention
SEQ ID NO: 22—Description of Artificial Sequence: second detection oligonucleotide probe used in the present invention
SEQ ID NO: 23—Description of Artificial Sequence: sense primer used in the present invention
SEQ ID NO: 24—Description of Artificial Sequence: antisense primer used in the present invention
SEQ ID NO: 25—Description of Artificial Sequence: first detection oligonucleotide probe used in the present invention
SEQ ID NO: 26—Description of Artificial Sequence: first detection oligonucleotide probe used in the present invention
SEQ ID NO: 27—Description of Artificial Sequence: first detection oligonucleotide probe used in the present invention
SEQ ID NO: 28—Description of Artificial Sequence: first detection oligonucleotide probe used in the present invention
SEQ ID NO: 29—Description of Artificial Sequence: second detection oligonucleotide probe used in the present invention
SEQ ID NO: 30—Description of Artificial Sequence: second detection oligonucleotide probe used in the present invention
SEQ ID NO: 31—Description of Artificial Sequence: second detection oligonucleotide probe used in the present invention
SEQ ID NO: 32—Description of Artificial Sequence: second detection oligonucleotide probe used in the present invention
Number | Date | Country | Kind |
---|---|---|---|
2007-322043 | Dec 2007 | JP | national |
2008-274783 | Oct 2008 | JP | national |